1-14 of 14
npm1 gene
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

Damodaran Narayanan, Olga Pozdnyakova, Robert P. Hasserjian, Sanjay S. Patel, Olga K. Weinberg
Journal: Blood Advances
Blood Adv (2021) 5 (11): 2539–2549.
https://doi.org/10.1182/bloodadvances.2021004250
Published: 2021
Includes: Supplemental data
Journal Articles

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia

Clinical Trials & Observations
Christopher J. Walker, Krzysztof Mrózek, Hatice Gulcin Ozer, Deedra Nicolet, Jessica Kohlschmidt, Dimitrios Papaioannou, Luke K. Genutis, Marius Bill, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Andrew J. Carroll, Richard M. Stone, Ramiro Garzon, John C. Byrd, Ann-Kathrin Eisfeld, Albert de la Chapelle, Clara D. Bloomfield
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1474–1482.
https://doi.org/10.1182/bloodadvances.2020003727
Published: 2021
Includes: Supplemental data
Journal Articles

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Clinical Trials & Observations
Curtis A. Lachowiez, Sanam Loghavi, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Kiran Naqvi, Yesid Alvarado, Musa Yilmaz, Nicholas Short, Maro Ohanian, Sherry R. Pierce, Keyur P. Patel, Wei Qiao, Jing Ning, Koji Sasaki, Koichi Takahashi, Elias Jabbour, Michael Andreeff, Farhad Ravandi, Hagop M. Kantarjian, Marina Konopleva, Courtney D. DiNardo
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1311–1320.
https://doi.org/10.1182/bloodadvances.2019001267
Published: 2020
Includes: Supplemental data
Journal Articles

The prognostic impact of FLT3 -ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

Clinical Trials & Observations
Gunnar Juliusson, Martin Jädersten, Stefan Deneberg, Sören Lehmann, Lars Möllgård, Lovisa Wennström, Petar Antunovic, Jörg Cammenga, Fryderyk Lorenz, Emma Ölander, Vladimir Lj Lazarevic, Martin Höglund
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1094–1101.
https://doi.org/10.1182/bloodadvances.2019001335
Published: 2020
Includes: Supplemental data
Journal Articles

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia

Clinical Trials & Observations
Kirk E. Cahill, Yasmin H. Karimi, Theodore G. Karrison, Nitin Jain, Margaret Green, Howard Weiner, Noreen Fulton, Sabah Kadri, Lucy A. Godley, Andrew S. Artz, Hongtao Liu, Michael J. Thirman, Michelle M. Le Beau, Megan E. McNerney, Jeremy Segal, Richard A. Larson, Wendy Stock, Olatoyosi Odenike
Journal: Blood Advances
Blood Adv (2020) 4 (4): 599–606.
https://doi.org/10.1182/bloodadvances.2019000795
Published: 2020
Includes: Supplemental data
Journal Articles

Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome

Emily F. Mason, Robert P. Hasserjian, Nidhi Aggarwal, Adam C. Seegmiller, Olga Pozdnyakova
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3322–3332.
https://doi.org/10.1182/bloodadvances.2019000328
Published: 2019
Includes: Supplemental data
Journal Articles

Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia

Norio Shiba, Kenichi Yoshida, Yusuke Hara, Genki Yamato, Yuichi Shiraishi, Hidemasa Matsuo, Yusuke Okuno, Kenichi Chiba, Hiroko Tanaka, Taeko Kaburagi, Masanobu Takeuchi, Kentaro Ohki, Masashi Sanada, Jun Okubo, Daisuke Tomizawa, Tomohiko Taki, Akira Shimada, Manabu Sotomatsu, Keizo Horibe, Takashi Taga, Souichi Adachi, Akio Tawa, Satoru Miyano, Seishi Ogawa, Yasuhide Hayashi
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3157–3169.
https://doi.org/10.1182/bloodadvances.2019000404
Published: 2019
Includes: Supplemental data
Journal Articles

CRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK + lymphoma after transplantation

Soumya Sundara Rajan, Lingxiao Li, Mercedes F. Kweh, Kranthi Kunkalla, Amit Dipak Amin, Nitin K. Agarwal, Francisco Vega, Jonathan H. Schatz
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1788–1794.
https://doi.org/10.1182/bloodadvances.2018025247
Published: 2019
Includes: Supplemental data
Journal Articles

Clinicopathologic and genetic characterization of nonacute NPM1 -mutated myeloid neoplasms

Clinical Trials & Observations
Sanjay S. Patel, Caleb Ho, Ryan N. Ptashkin, Sam Sadigh, Adam Bagg, Julia T. Geyer, Mina L. Xu, Thomas Prebet, Emily F. Mason, Adam C. Seegmiller, Elizabeth A. Morgan, David P. Steensma, Eric S. Winer, Waihay J. Wong, Robert P. Hasserjian, Olga K. Weinberg
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1540–1545.
https://doi.org/10.1182/bloodadvances.2019000090
Published: 2019
Journal Articles

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Clinical Trials & Observations
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, Keyur Patel, Irene Ganan-Gomez, Elias Jabbour, Tapan Kadia, Farhad Ravandi, Courtney DiNardo, Gautham Borthakur, Koichi Takahashi, Marina Konopleva, Rami S. Komrokji, Amy DeZern, Teodora Kuzmanovic, Jaroslaw Maciejewski, Sherry Pierce, Simona Colla, Mikkael A. Sekeres, Hagop Kantarjian, Carlos Bueso-Ramos, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2019) 3 (6): 922–933.
https://doi.org/10.1182/bloodadvances.2018026989
Published: 2019
Includes: Supplemental data
Journal Articles

NPM1 mutated AML can relapse with wild-type NPM1 : persistent clonal hematopoiesis can drive relapse

Clinical Trials & Observations
Alexander Höllein, Manja Meggendorfer, Frank Dicker, Sabine Jeromin, Niroshan Nadarajah, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach
Journal: Blood Advances
Blood Adv (2018) 2 (22): 3118–3125.
https://doi.org/10.1182/bloodadvances.2018023432
Published: 2018
Journal Articles

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter

Gregory W. Roloff, Elizabeth A. Griffiths
Journal: Blood Advances
Blood Adv (2018) 2 (21): 3070–3080.
https://doi.org/10.1182/bloodadvances.2018020206
Published: 2018
Journal Articles

Prognostic impact of low allelic ratio FLT3- ITD and NPM1 mutation in acute myeloid leukemia

Clinical Trials & Observations
Masahiro Sakaguchi, Hiroki Yamaguchi, Yuho Najima, Kensuke Usuki, Toshimitsu Ueki, Iekuni Oh, Sinichiro Mori, Eri Kawata, Nobuhiko Uoshima, Yutaka Kobayashi, Shinichi Kako, Kenji Tajika, Seiji Gomi, Katsuhiro Shono, Kensuke Kayamori, Masao Hagihara, Junya Kanda, Hitoji Uchiyama, Junya Kuroda, Naoyuki Uchida, Yasushi Kubota, Shinya Kimura, Saiko Kurosawa, Nana Nakajima, Atsushi Marumo, Ikuko Omori, Yusuke Fujiwara, Shunsuke Yui, Satoshi Wakita, Kunihito Arai, Tomoaki Kitano, Kazuhiko Kakihana, Yoshinobu Kanda, Kazuteru Ohashi, Takahiro Fukuda, Koiti Inokuchi
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2744–2754.
https://doi.org/10.1182/bloodadvances.2018020305
Published: 2018
Includes: Supplemental data
Journal Articles

Co-occurrence of FLT3 -TKD and NPM1 mutations defines a highly favorable prognostic AML group

Clinical Trials & Observations
Prajwal Boddu, Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Naval Daver, Sherry Pierce, Michael Andreeff, Farhad Ravandi, Jorge Cortes, Steven M. Kornblau
Journal: Blood Advances
Blood Adv (2017) 1 (19): 1546–1550.
https://doi.org/10.1182/bloodadvances.2017009019
Published: 2017
Includes: Supplemental data